Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study
- Conditions
- Adenocarcinoma of Head of Pancreas
- Registration Number
- NCT01455610
- Lead Sponsor
- Meng Su Zeng
- Brief Summary
The purpose of this multicenter and double-blind clinical trial is to prospectively assess the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy in respectability of pancreatic head cancer with contrasted-enhanced MDCT and its various post processing techniques, taking operational and pathological records as the gold standard.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 140
- Patients with (or suspected) pancreatic head cancer
- Being examined by contrasted-enhanced MDCT
- Receiving surgical treatment (including palliative surgery) in all research centers
- Patients having (or suspected) pregnancy or breast-feeding
- Patients having allergic reactions to iodinated contrast agents or Hypersensitivity reactions to allergens(including drugs)
- Patients receiving ERCP before contrasted-enhanced MDCT examination
- Patients without surgery because of a high degree of surgical risk
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Radiology Department, Changhai Hospital Affiliated to the Second Military Medical University
🇨🇳Shanghai, Shanghai, China
Radiology Department, Ruijing Hospital, Shanghai Jiaotong University
🇨🇳Shanghai, Shanghai, China
Radiology Department, Cancer Hospital, Fuandan University
🇨🇳Shanghai, Shanghai, China
Radiology Department, Zhongshan Hospital, Fudan University
🇨🇳Shanghai, Shanghai, China
Radiology Department, Huashan Hospital, Fudan University
🇨🇳Shanghai, Shanghai, China
Radiology Department, Huadong Hospital, Fudan University
🇨🇳Shanghai, Shanghai, China